<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03078309</url>
  </required_header>
  <id_info>
    <org_study_id>0007-17-HMO</org_study_id>
    <nct_id>NCT03078309</nct_id>
  </id_info>
  <brief_title>The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients</brief_title>
  <official_title>A Controlled Study of the Effect of Cannabis on Visual Functions in Healthy Subjects and in Retinitis Pigmentosa Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hebrew University of Jerusalem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Medical Marijuana is used widely, and its effects on the visual system and the function of
      the retina have not been investigated thoroughly. Some evidence suggests that cannabinoids
      may be beneficial in certain degenerative diseases of the retina.

      The purpose of the study is

        1. To determine whether cannabis derivatives affect the visual functions in healthy adults

        2. To examine the effect of cannabis derivatives on the retina of retinitis pigmentosa
           patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty five healthy subjects and 25 retinitis pigmentosa patients will be recruited and will
      sign an informed consent form. An initial eye exam will include visual acuity and stereo
      vision, eye movements and eye movement recording, a full slit lamp eye exam, intra-ocular
      pressure measurement, visual field, OCT and electrophysiology. The subjects will receive a
      single sublingual dose of cannabis (THC:CBD 1:1, THC 5 mg, or THE:CBD 1:40, THC 5 mg), and
      will undergo the above examination again. Subjects will be monitored for 5 hours after the
      administration of cannabis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm 1 - healthy subjects. Arm 2 - subjects with retinitis pigmentosa All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Electrophysiology will be analyzed by a blinded investigator.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Electroretinogram - mixed cone-rod response, cone flicker, rod response</measure>
    <time_frame>3 hours</time_frame>
    <description>microvolt</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electroretinogram - cone flicker latency</measure>
    <time_frame>3 hours</time_frame>
    <description>milliseconds</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>3 hours</time_frame>
    <description>LogMAR ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titmus stereo eye movements</measure>
    <time_frame>3 hours</time_frame>
    <description>seconds of arc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eye movements</measure>
    <time_frame>3 hours</time_frame>
    <description>degrees/second</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra ocular pressure</measure>
    <time_frame>3 hours</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular thickness (OCT)</measure>
    <time_frame>3 hours</time_frame>
    <description>micrometers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <condition>Retinal Degeneration</condition>
  <condition>Cannabis</condition>
  <arm_group>
    <arm_group_label>healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retinitis Pigmentosa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cannabis</intervention_name>
    <description>single dose sublingual cannabis (THC:CBD 1:1, THC:CBD 1:40)</description>
    <arm_group_label>healthy</arm_group_label>
    <arm_group_label>Retinitis Pigmentosa</arm_group_label>
    <other_name>cannabidiol</other_name>
    <other_name>THC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  consenting adults

          -  generally healthy with or without retinitis pigmentosa

        Exclusion Criteria:

          -  chronic or acute disease other than retinitis pigmentosa

          -  use of medication

          -  congestive heart failure

          -  recent use of illicit drugs (past month)

          -  history of drug dependency

          -  history of psychiatric disorder in subject or immediate relatives

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hadas Mechoulam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hadas Mechoulam, MD</last_name>
    <phone>9293077002</phone>
    <email>hadasm@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hadas Lemberg, PhD</last_name>
    <phone>00 972 2 6777572</phone>
    <email>lhadas@hadassah.org.il</email>
  </overall_contact_backup>
  <reference>
    <citation>Lax P, Esquiva G, Altavilla C, Cuenca N. Neuroprotective effects of the cannabinoid agonist HU210 on retinal degeneration. Exp Eye Res. 2014 Mar;120:175-85. doi: 10.1016/j.exer.2014.01.019. Epub 2014 Feb 1.</citation>
    <PMID>24495949</PMID>
  </reference>
  <reference>
    <citation>Russo EB, Merzouki A, Mesa JM, Frey KA, Bach PJ. Cannabis improves night vision: a case study of dark adaptometry and scotopic sensitivity in kif smokers of the Rif mountains of northern Morocco. J Ethnopharmacol. 2004 Jul;93(1):99-104.</citation>
    <PMID>15182912</PMID>
  </reference>
  <reference>
    <citation>Lyons CJ, Robson AG. Retinal Ganglion Cell Dysfunction in Regular Cannabis Users: Is the Evidence Strong Enough to Consider an Association? JAMA Ophthalmol. 2017 Jan 1;135(1):60-61. doi: 10.1001/jamaophthalmol.2016.4780.</citation>
    <PMID>27930772</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2017</study_first_submitted>
  <study_first_submitted_qc>March 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hadassah Medical Organization</investigator_affiliation>
    <investigator_full_name>Hadas MECHOULAM</investigator_full_name>
    <investigator_title>senior physician</investigator_title>
  </responsible_party>
  <keyword>retinitis pigmentosa</keyword>
  <keyword>retinal degeneration</keyword>
  <keyword>cannabis</keyword>
  <keyword>THC</keyword>
  <keyword>CBD</keyword>
  <keyword>electrophysiology</keyword>
  <keyword>visual functions</keyword>
  <keyword>eye</keyword>
  <keyword>retina</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
    <mesh_term>Retinal Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

